Literature DB >> 26220616

Inhibitors of Ceramidases.

Essa M Saied1, Christoph Arenz2.   

Abstract

The topic of ceramidases has experienced an enormous boost during the last few years. Ceramidases catalyze the degradation of ceramide to sphingosine and fatty acids. Ceramide is not only the central hub of sphingolipid biosynthesis and degradation, it is also a key molecule in sphingolipid signaling, promoting differentiation or apoptosis. Acid ceramidase inhibition sensitizes certain types of cancer to chemo- and radio-therapy and this is suggestive of a role of acid ceramidase inhibitors as chemo-sensitizers which can act synergistically with chemo-therapeutic drugs. In this review, we summarize the development of ceramide analogues as first-generation ceramidase inhibitors together with data on their activity in cells and disease models. Furthermore, we describe the recent developments that have led to highly potent second-generation ceramidase inhibitors that act at nanomolar concentrations. In the third part, various assays of ceramidases are described and their relevance for accurately measuring ceramidase activities and for the development of novel inhibitors is highlighted. Besides potential clinical implications, the recent improvements in ceramidase inhibition and assaying may help to better understand the mechanisms of ceramide biology.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Ceramidase Inhibitors; Ceramidases; Ceramide homeostasis; Enzyme assays; Sphingolipids

Mesh:

Substances:

Year:  2015        PMID: 26220616     DOI: 10.1016/j.chemphyslip.2015.07.009

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  8 in total

Review 1.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

Review 2.  Targeting Sphingosine Kinases for the Treatment of Cancer.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

3.  Protective Effect of Pycnogenol against Methotrexate-Induced Hepatic, Renal, and Cardiac Toxicity: An In Vivo Study.

Authors:  Faten Al-Abkal; Basel A Abdel-Wahab; Hanaa F Abd El-Kareem; Yasser M Moustafa; Dina M Khodeer
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

4.  The Binary Mixtures of Lambda-Cyhalothrin, Chlorfenapyr, and Abamectin, against the House Fly Larvae, Musca domestica L.

Authors:  Doaa F El Sherif; Nagat H Soliman; Khalid S Alshallash; Nevin Ahmed; Mervat A R Ibrahim; Kholoud A Al-Shammery; Areej A Al-Khalaf
Journal:  Molecules       Date:  2022-05-12       Impact factor: 4.927

5.  Insights into the Antimicrobial, Antioxidant, Anti-SARS-CoV-2 and Cytotoxic Activities of Pistacia lentiscus Bark and Phytochemical Profile; In Silico and In Vitro Study.

Authors:  Samy Selim; Mohammed S Almuhayawi; Mohanned T Alharbi; Soad K Al Jaouni; Afaf Alharthi; Basel A Abdel-Wahab; Mervat A R Ibrahim; Amnah Mohammed Alsuhaibani; Mona Warrad; Khaled Rashed
Journal:  Antioxidants (Basel)       Date:  2022-05-09

Review 6.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

Review 7.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Targeting the Sphingolipid Rheostat in Gliomas.

Authors:  Faris Zaibaq; Tyrone Dowdy; Mioara Larion
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.